熱門資訊> 正文
Enveric Biosciences GAAP每股收益为-10.81美元
2025-11-15 05:49
- Enveric Biosciences press release (ENVB): Q3 GAAP EPS of -$10.81.
- The net loss for the quarter included approximately $0.2 million in non-cash expenses related to stock-based compensation and other non-cash charges.
- As of September 30, 2025, Enveric had cash and cash equivalents of $3.8 million. The Company continues to fund its operations through the use of various financing tools.
- The Company has raised net proceeds of $7.9 million for the nine months ended September 30, 2025.
More on Enveric Biosciences
- AbbVie could face patent battle over depression asset gained in Gilgamesh deal
- Seeking Alpha’s Quant Rating on Enveric Biosciences
- Financial information for Enveric Biosciences
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
